EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32479-7
Abstract: Canagliflozin (CANA) reduces the risk of cardiovascular (CV) events and kidney failure in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Inherent in its mechanism of action is enhanced natriuresis and… read more here.
Keywords: canagliflozin cardiovascular; safety outcomes; renal safety; safety ... See more keywords
Canagliflozin and Cardiovascular disease- results of the CANVAS trial
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Community Hospital Internal Medicine Perspectives"
DOI: 10.1080/20009666.2018.1521245
Abstract: ABSTRACT Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium–glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to… read more here.
Keywords: trial; canagliflozin cardiovascular; results canvas; canvas trial ... See more keywords
Canagliflozin and cardiovascular outcomes in Type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2020 at "Future cardiology"
DOI: 10.2217/fca-2020-0029
Abstract: SGLT2 inhibitors have risen to prominence in recent years as Type 2 diabetes mellitus medications with favorable effects on cardiovascular (CV) and renal outcomes. Canagliflozin is a US FDA-approved SGLT2 inhibitor that has demonstrated CV and renal… read more here.
Keywords: canagliflozin cardiovascular; cardiology; cardiovascular outcomes; outcomes type ... See more keywords